Oragenics initiates COVID-19 vaccine hamster challenge study

Green and blue coronavirus cells under magnification intertwined with DNA cell structure
matejmo/E+ via Getty Images

  • Oragenics (NYSE:OGEN) announces the initiation of a study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study.
  • The study looks to provide data for several vaccine formulations, using adjuvants specific for both intranasal and intramuscular routes of administration.
  • The study is being conducted by the company’s Canadian collaborator with results expected in November.
  • The company believes that the results from the hamster study will further the development strategy for Terra CoV-2.
  • It also said that the findings from a second preclinical study will be a part of its Investigational New Drug filing to the U.S. FDA, expected to be made in the first quarter of 2022.
  • Shares up nearly 2% premarket.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.